Evidence grades (GRADE-adapted): A high — multiple well-conducted RCTs or systematic reviews converge. B moderate — single pivotal RCT or consistent observational evidence. C limited — single observational study, mechanistic, or expert consensus. D preclinical / hypothesis-generating.
Global breast cancer and TNBC context
The GLOBOCAN 2020 estimates indicated approximately 2.26 million new breast cancer cases globally per year, making breast cancer the most commonly diagnosed cancer worldwide[1]A. Age-standardized incidence rates vary roughly 4-fold across regions, with the highest rates in high-income Western countries (Australia, Western Europe, North America) and the lowest in South-Central Asia and parts of sub-Saharan Africa. Breast cancer mortality patterns differ from incidence: the ratio of mortality to incidence is substantially higher in low- and middle-income countries, reflecting later-stage diagnosis and limited treatment access.
Within breast cancer, TNBC represents approximately 10–20% of cases when measured globally, but the proportion varies markedly across populations.
Regional variation in TNBC proportion
Observational evidence from population-based registries and large hospital series documents substantial regional variation in the TNBC fraction among breast cancers:
- Sub-Saharan West Africa — TNBC reaches 30–50% of breast cancers in series from Nigeria, Ghana, Senegal, and Mali. The Nigerian Breast Cancer Study and series from Korle Bu Teaching Hospital (Ghana) are reference cohorts. The high TNBC fraction is paired with younger age at diagnosis and aggressive disease presentations.
- African-American populations in the US — TNBC accounts for ~20% of breast cancers in Black women, compared with ~10% in White women. The disparity is largely driven by basal-like TNBC subtype enrichment in African-ancestry populations (see ancestry disparities synthesis when available).
- South Asia (India, Pakistan, Bangladesh) — TNBC reaches 25–35% in several large hospital-based series. The proportion is higher than in East Asian cohorts despite some geographic proximity, suggesting genetic ancestry and/or reproductive epidemiology differences.
- East Asia (China, Japan, Korea) — TNBC accounts for ~10–15% of breast cancers, the lower end of the global range.
- Western Europe and North America (White populations) — TNBC accounts for ~10–15% of breast cancers, similar to East Asia.
- Latin America — intermediate, with substantial variation by country. Brazilian, Mexican, and Argentinian series report TNBC fractions of 15–25%, with admixed-ancestry populations showing higher fractions than predominantly European-ancestry populations.
Reproductive epidemiology correlates
Several reproductive factors are differentially associated with TNBC vs hormone receptor-positive breast cancer risk:
- Young age at first full-term pregnancy reduces overall breast cancer risk but is associated with increased TNBC risk in some cohorts
- High parity (multiple full-term pregnancies) reduces hormone-receptor-positive breast cancer risk but is associated with elevated TNBC risk
- Short or absent breastfeeding is associated with elevated TNBC risk; some evidence suggests breastfeeding has greater protective effect against TNBC than against HR+ disease
- Younger age at menarche increases overall breast cancer risk; the TNBC-specific effect is less clear
- Obesity in premenopausal women is associated with elevated TNBC risk
These reproductive factor distributions vary across populations and partially correlate with the TNBC fraction differences. In populations with high parity, early childbearing, and lower breastfeeding rates relative to the overall reproductive load, TNBC fractions are higher. However, reproductive epidemiology does not fully explain the regional variation; genetic ancestry effects (independent of reproductive factors) are also implicated (see synthesis on ancestry disparities).
GLOBOCAN methodology and limitations
The GLOBOCAN estimates are produced by the International Agency for Research on Cancer (IARC) and are the standard reference for global cancer incidence and mortality. The estimates are based on:
- Population-based cancer registries where available (typically covering <5% of global population)
- Modeled estimates for countries without population-based registries, using regional aggregates and demographic indicators
- Mortality-to-incidence ratios where mortality data are available but incidence data are not
- Age-standardization to the World Standard Population for cross-country comparison
Important limitations for TNBC interpretation:
- GLOBOCAN reports overall breast cancer incidence, not TNBC-specific incidence. TNBC fractions must be inferred from hospital series or specialty registries
- IHC testing for ER/PR/HER2 is not uniformly available in low-income settings; reported TNBC fractions may reflect non-standardized testing
- Hospital-based series are not representative of population incidence in settings with limited healthcare access
- Age and stage at presentation differ substantially across regions, complicating direct comparison
Trends over time
Limited longitudinal data make trend analysis difficult, but several observations:
- Breast cancer incidence is rising globally, particularly in low- and middle-income countries undergoing demographic transition (rising age, urbanization, fertility decline)
- TNBC-specific incidence trends are less clear because of inconsistent IHC testing over time
- Some evidence suggests TNBC incidence is rising in some Asian and Latin American populations, possibly reflecting demographic and reproductive transition
- In high-income Western populations, TNBC incidence has been relatively stable
Evidence table
| Region/Population | TNBC fraction (approx.) | Median age at dx |
|---|---|---|
| Sub-Saharan West Africa | 30–50% | 45–50 |
| African-American (US) | ~20% | ~55 |
| South Asia | 25–35% | ~50 |
| Latin America (mixed-ancestry) | 15–25% | ~55 |
| White (US/Europe) | 10–15% | ~60 |
| East Asia | 10–15% | ~50 |
Mortality disparity context
The global TNBC mortality burden is concentrated in regions with high TNBC fractions and limited treatment access. While modern TNBC therapy (KEYNOTE-522, sacituzumab govitecan, T-DXd for HER2-low, PARP inhibitors for BRCA-mutated) has substantially improved outcomes in high-income settings, access to these therapies remains limited in low- and middle-income countries. The mortality-to-incidence ratio for TNBC in sub-Saharan Africa is substantially higher than for HR+ breast cancer in the same regions, reflecting both biological aggression and treatment access gaps.
Open questions and active investigation
- Whether the West African TNBC fraction reflects ancestry-driven biology or environmental/reproductive epidemiology. Both contribute; the relative weights are an active research question with implications for prevention.
- Whether TNBC incidence is changing in populations undergoing demographic transition. Cross-sectional data show high TNBC fractions in current populations; longitudinal studies could distinguish stable patterns from changing patterns.
- Population-specific tumor biology. Whether TNBC arising in different populations differs biologically beyond fraction (e.g., subtype distribution, mutation patterns, immune infiltration) is being studied through international consortia (ICGC, TCGA expansion projects).
- Access to standardized IHC testing. Improving the quality and uniformity of ER/PR/HER2 testing in low-resource settings is a precondition for accurate TNBC incidence measurement and for triage to appropriate therapy.
- Whether modern targeted therapies can be deployed in resource-limited settings. The cost and infrastructure requirements of pembrolizumab, ADCs, and PARP inhibitors are substantial barriers; cost-effective deployment strategies are an active research focus.
For ancestry-driven disparities in TNBC incidence and outcomes within the US, see the (forthcoming) ancestry disparities synthesis. For age-related epidemiology, see the (forthcoming) age and premenopausal TNBC synthesis.
References
Each citation links to the original publication via DOI. The same records are searchable in the evidence library by title or DOI.
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660. ↩
- Newman LA, Kaljee LM. Health disparities and triple-negative breast cancer in African American women: a review. JAMA Surg. 2017;152(5):485–493. doi:10.1001/jamasurg.2017.0005. ↩
Last reviewed: 2026-06-04. Researcher-layer synthesis page. Evidence grades follow the GRADE-adapted rubric defined at the top of this page.